Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

American Journal of Gastroenterology

Volumn 103, Issue 4, 2008, Pages 944-948

  Ainsworth, Mark A ^a   Bendtzen, Klaus ^b,c   Brynskov, Jørn ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c BioMonitor ApS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41849135759     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01638.x     Document Type: Article

References (20)

1. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999 117 : 761 9.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. ACCENT I Study Group. Lancet 2002 359 : 1541 9.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 340 : 1398 405.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 85.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 76.
6. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005 128 : 1805 11.
7. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999 354 : 1932 9.
8. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Arthritis Rheum 2004 50 : 1051 65.
9. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002 46 : 1451 9.
10. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor-α inhibitor infliximab. Arthritis Rheum 2006 54 : 3782 9.
11. Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003 5 : 501 5.
12. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 8.
13. Bendtzen K. Detection of anti-TNF biopharmaceuticals. http://www.biomon.dk/biom/70TNF/_aTNF.htm (accessed October 24, 2007).
14. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004 2 : 542 53.
15. Hennig C, Rink L, Fagin U, et al. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000 235 : 71 80.
16. Bendtzen K. Anti-IFN BAb and NAb antibodies: A minireview. Neurology 2003 61 (Suppl 5 S6 10.
17. Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003 48 : 68 75.
18. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005 72 : 250 6.
19. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. Gastroenterology 2003 124 : 917 24.
20. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002 97 : 2350 6.